Next Article in Journal
Evofosfamide Enhances Sensitivity of Breast Cancer Cells to Apoptosis and Natural-Killer-Cell-Mediated Cytotoxicity Under Hypoxic Conditions
Previous Article in Journal
Retrospective Evaluation of Baseline Amino Acid PET for Identifying Future Regions of Tumor Recurrence in High-Grade Glioma Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 12
10.3390/cancers17121987
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Vitamin D Concentration Among Women with Gynecological Cancers

by
Marcin Adam Zębalski
1,
Patrycja Zębalska
1,
Aleksandra Krzywon
2,* and
Krzysztof Nowosielski
1,*
1
Department of Gynecology, Obstetrics and Gynecological Oncology, University Clinical Center of the Medical University of Silesia, 40-752 Katowice, Poland
2
Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland
*
Authors to whom correspondence should be addressed.
Cancers 2025, 17(12), 1987; https://doi.org/10.3390/cancers17121987
Submission received: 12 April 2025 / Revised: 6 June 2025 / Accepted: 11 June 2025 / Published: 14 June 2025
(This article belongs to the Section Cancer Epidemiology and Prevention)
Browse Figures
Versions Notes

Simple Summary

Vitamin D deficiency is widespread, and the incidence of cancer continues to rise. Numerous studies have shown a link between vitamin D deficiency and cancer incidence. However, no studies to date have examined the association between vitamin D status and distinct histopathological types of gynecological cancers. Ensuring proper vitamin D levels may serve as a protective factor against gynecological malignancies.

Abstract

Background: Although vitamin D supplementation is simple, inexpensive, and safe, vitamin D deficiency remains widespread, especially in developing communities. The aim of our study was to assess vitamin D levels among patients with gynecological cancers and compare them with those in patients with benign tumors living in rural and urban areas. Methods: This is a clinical retrospective study covering data analysis from March 2021 to July 2023. A total of 686 patients with uterine or ovarian tumors were analyzed. An electrochemiluminescence immunoassay method was used to assess vitamin D concentrations. Other laboratory blood tests were also performed on the admission day. Results: A significant reduction in vitamin D levels in oncological vs. non-oncological patients (median 23 (17, 33) ng/mL vs. 28 [21, 36] ng/mL, p < 0.001) was observed. The lowest vitamin D concentration was found in patients with ovarian cancer (median 22 (16, 32) ng/mL), followed by those with endometrial cancer and cervical cancer—median 24 (18, 35) ng/mL and 26 (20, 31) ng/mL, respectively). We found no differences in the vitamin D concentration between various histopathological types of ovarian cancers (p = 0.07). No correlation between the vitamin D concentration and age (r = 0.03, p > 0.05) was noted. A negligible negative correlation between vitamin D levels and BMI was observed (r = −0.095, p = 0.03). Additionally, those living in cities had a significantly reduced vitamin D concentration compared to those living in rural areas. No significant differences were demonstrated in vitamin D concentrations between malignant and benign tumors among patients living in rural areas (p = 0.17). Conclusions: Gynecological oncology patients have significantly lower vitamin D levels compared to non-oncological patients. In our patient population, ovarian and endometrial cancers were frequently associated with vitamin D deficiency. While this observation does not establish causation, it highlights the potential value of monitoring vitamin D levels and addressing deficiencies as part of broader cancer prevention and management strategies.

1. Introduction

Calcitriol, the active form of vitamin D3, is a fat-soluble vitamin mostly produced in the human body through exposure to sunlight. Under ultraviolet B (UVB) radiation, 7-dehydrocholesterol in the skin is converted to cholecalciferol, which is then hydroxylated in the liver to form 25-hydroxyvitamin D3, and subsequently in the kidneys to 1,25-dihydroxyvitamin D3, the main active hormone. The secondary source of vitamin D3 is dietary intake, mainly from fish, butter, eggs and vegetable oils [1].
Vitamin D is mainly responsible for calcium and phosphate metabolism. Nevertheless, some authors claim it should be called a hormone because it is responsible for many regulatory processes in the body, including the expression of many genes that may play a role in the pathogenesis of cancer and the modulation of the immune system [2]. In addition to its anti-cancer effect, vitamin D3 is believed to have a positive effect on the cardiovascular system, reducing the risk of cardiovascular events, and positively influencing the immune system and carbohydrate metabolism [3,4].
In recent years, more attention has been paid to the anti-cancer effect of vitamin D. Many studies have noted a relationship between low vitamin D3 concentrations and a higher incidence of cancer [2,5]. It has been observed that vitamin D may have a protective effect on gynecological cancers including ovarian, endometrial and cervical cancer, as well as many other types of cancer, such as colon, breast, prostate, melanoma, and some leukemias and lymphomas [1,3,6].
The effect of vitamin D3 on the etiopathogenesis of gynecological cancers is not fully elucidated. However, many studies postulate that adequate vitamin D3 concentrations may have a protective effect against ovarian cancer [1,6,7,8,9,10,11,12,13,14] and cervical cancer [15,16,17,18,19]. The evidence for an association between vitamin D and endometrial cancer is not fully consistent [8].
Vitamin D3 has been shown to inhibit the proliferation of cancer cells in vitro [8]. The inhibition of cancer cell division is achieved by blocking cell cycle checkpoints, reducing transcription factors, and influencing the epithelial–mesenchymal transition, which results in the inhibition of cancer cell migration and invasion. Moreover, vitamin D reduces the level of telomerase in ovarian cancer cells, which translates into the induction of apoptosis [12,20,21,22,23,24,25]. The result is the inhibition of the growth of many ovarian cancer cell lines [25]. In vivo and in vitro studies have also demonstrated the effect of vitamin D on inhibiting the metastasis of ovarian cancer to the omentum [26].
The aim of this study was to evaluate the vitamin D concentration in patients with gynecological cancers compared to non-oncological patients and to assess the vitamin D concentration depending on the histopathological type of the tumor.

2. Materials and Methods

2.1. Patients

This single-center, retrospective analytical study assesses vitamin D levels in patients who underwent surgery at the Department of Obstetrics, Gynecology, and Oncologic Gynecology in Katowice, Poland, due to gynecological malignant tumors and oncologically suspicious uterine and adnexal tumors.
Vitamin D3 levels were measured in all patients with gynecological cancers and those with suspected ovarian or uterine tumors. Blood samples for vitamin D assessment were collected in the morning as part of routine preoperative laboratory testing, on the day of hospital admission (i.e., the day before the scheduled surgery). The total serum vitamin D levels were measured using an electrochemiluminescence immunoassay on the Cobas e402 (Roche, Basel, Switzerland).
The exclusion criteria included patients admitted to the hospital for purposes other than surgery due to gynecological cancer or its suspicion.
For the correct serum levels of vitamin D, we used a range between 30 and 100 ng/mL in accordance with applicable standards [27,28,29].

2.2. Statistical Analysis

Medians with interquartile ranges (25% to 75%, IQR) and means with standard deviations were provided for continuous variables. The Wilcoxon rank sum test (for two groups), the Kruskal–Wallis H test (for more than two groups) and the post hoc Dunn test were used for continuous variables. A one-sample Wilcoxon signed rank test was performed for the changes measured between two time points. The Spearman correlation coefficient was used to calculate a measure of correlation according to the following classification: 0.0 ≤ |r| < 0.1 negligible correlation, 0.1 ≤ |r| ≤ 0.39 weak correlation, 0.4 ≤ |r| ≤ 0.69 moderate correlation, 0.7 ≤ |r| ≤ 0.89 strong correlation, 0.9 ≤ r ≤ 1 very strong correlation. Statistical significance was defined as a two-sided p-value < 0.05. All analyses were performed using the R environment for statistical computing (version 4.0.1, R Foundation for Statistical Computing, Vienna, Austria, http://www.r-project.org, accessed on 6 June 2020).

3. Results

3.1. Patients

In this study, we analyzed the medical records of 686 patients hospitalized between March 2021 and July 2023 at the Department of Obstetrics, Gynecology, and Oncologic Gynecology in Katowice, Poland. All patients were white, Polish-born women.
We divided our cohort (n = 686 patients) into oncological patients with a histopathologically confirmed malignancy postoperatively (Group A—oncological patients; n = 472, 69%) and non-oncological patients (Group B—non-oncological patients, n = 214; 31%). The basic characteristics of the study participants are summarized in Table 1. Both groups were comparable in terms of age (p > 0.05), BMI (p > 0.05), comorbidities like diabetes, hypertension and ischemic heart disease (p > 0.05), smoking status (p > 0.05), the frequency of oral contraceptive use and urban residency (p > 0.05).
Among oncological patients, 283 (60%) were patients with ovarian cancer, 135 (29%) had endometrial cancer and 54 (11%) had cervical cancer. Among non-oncological patients, 52 (24.3%) had uterine fibroid and 162 (75.7%) had benign ovarian lesions. Detailed histopathological results are presented in Table 2.

3.2. Surgery

Of the total patients, 266 patients (39%) underwent laparotomy, 404 (59%) underwent laparoscopy, and 16 patients (2%) were disqualified from surgery due to their poor general condition and failure to meet anesthesia qualifications. In patients who were not eligible for surgery, the diagnosis of cancer was either confirmed or excluded through dilation and curettage (D&C), cervical biopsies, or CT-guided biopsy for histopathological examination.

3.3. Vitamin D Concentration

We have shown that the median concentration of vitamin D is significantly reduced in oncological patients compared to non-oncological patients (23 (17, 33) ng/mL vs. 28 (21, 36) ng/mL, p < 0.001)—Figure 1.
Vitamin D deficiency was observed in 69% of oncological patients compared to 55% of non-oncological patients (p < 0.001).
Among oncological patients, those with ovarian cancer had the lowest median vitamin D concentration (22 (16, 32) ng/mL), followed by patients with endometrial cancer (24 (18, 35) ng/mL) and cervical cancer (26 (20, 31) ng/mL). Compared to non-oncological patients, significantly lower levels were found in ovarian and endometrial cancer patients (p < 0.001), whereas the difference for cervical cancer was not statistically significant (p = 0.1) (Table 3).
Among ovarian cancer patients, the most common ovarian cancers were serous adenocarcinoma (169 patients, 60%), endometroid adenocarcinoma (15 patients, 5%), clear cell carcinoma (11 patients, 4%), and borderline tumors (34 patients, 12%). We assessed the vitamin D levels in patients with various histopathological types of ovarian cancer. Due to the small sample size, patients with mucinous adenocarcinoma (5 patients, 2%), undifferentiated carcinoma (3 patients, 1%) and other rare subtypes were excluded from further analysis. No significant differences (p = 0.07) in vitamin D concentrations were observed between various histopathological types of ovarian malignant tumors, as shown in Figure 2.
No correlation was found between vitamin D concentrations and age (r = 0.03, p > 0.05). A negligible negative correlation was observed with BMI (r = −0.095, p = 0.03).
No significant difference in vitamin D levels was found between rural and urban residents overall (median 26 (20, 33) ng/mL vs. 24 (18, 34) ng/mL, p > 0.05). However, when stratified by disease status, urban oncological patients had significantly lower vitamin D levels than their non-oncological counterparts (p < 0.001), a difference not observed in rural patients (p = 0.11) (Table 4).
Since 2021, the Department of Obstetrics, Gynecology, and Oncologic Gynecology in Katowice has implemented a prehabilitation program, which includes correcting vitamin D deficiency preoperatively. Among the 472 oncological patients, 110 participated in this program. A significant increase in vitamin D concentrations was observed during the prehabilitation period (median increase: 8 (1, 18) ng/mL, p < 0.001 Table 5).

4. Discussion

This retrospective analysis revealed significantly lower vitamin D levels in oncological compared to non-oncological patients, especially among those with ovarian and endometrial cancer. No significant differences were found among various histological types of gynecological cancers. These findings align with the existing literature, which frequently reports vitamin D deficiency in cancer patients.
Vitamin D deficiency is widespread, especially in developed countries, and is strongly influenced by geographic latitude. Research shows that deficiency (25-OH-D < 20 ng/mL) affects around 40% of Europeans and 22% of Americans and Canadians [30,31].
The primary source of vitamin D is cutaneous synthesis via UVB radiation. Dietary intake and supplementation are secondary [21,32,33,34]. Skin synthesis is significantly more effective, as shown by Punnonen et al., who found comparable levels of fat-soluble vitamins A and E between Finnish and Floridian women but double the vitamin D levels in the latter [34].
There are many factors that limit the maintenance of appropriate vitamin D concentrations. One of the main factors is the geographical latitude inhabited by a given population. In addition, a low number of sunny days per year and a lack of skin exposure to sunlight further contribute to Vitamin D deficiency. The use of sunscreen, which limits vitamin D synthesis despite sun exposure, is another factor. Moreover, a patient’s BMI, skin melanin concentration, and skin pigmentation also influence vitamin D synthesis [3,5,21,31,35,36,37].
In 1980, the Garland brothers noticed a link between living at higher latitudes, vitamin D deficiency, and an increased risk of malignant tumors [38]. Since then, numerous studies have supported a link between sunlight exposure, vitamin D levels, and cancer occurrence [1,3,5,6,7,8,9,10,11,12,13,14,15,38,39,40,41,42,43,44]. In our study, we found significantly lower vitamin D levels in patients with ovarian cancer compared to those with benign lesions. Similar findings were reported by Bakhru et al. and Web et al., who found significantly lower vitamin D concentrations in ovarian cancer patients compared to healthy individuals [44,45]. Additionally, higher vitamin D levels in ovarian cancer patients were associated with longer survival [7,45,46]. A meta-analysis by Keum et al. showed that vitamin D3 supplementation was associated with a 13% reduction in cancer mortality [47].
However, not all studies confirm a link between vitamin D and the incidence of ovarian cancer [42,48,49,50,51,52]. One Mendelian randomization study found little evidence of a linear association between the genetic determinants of circulating vitamin D and ovarian cancer risk, although the possibility of a low magnitude having clinically relevant effects could not be ruled out [48]. In a study by Sajo et al., no clear association was found between serum vitamin D deficiency and the risk of ovarian cancer, although the median vitamin D levels were significantly lower in ovarian cancer patients than in cancer-free individuals (33.8 (23.0, 53.0) nmol/L vs. 50.0 (32.5, 93.0) nmol/L). This study was conducted in Africa, where sun exposure is significantly higher than in Europe or the U.S. [49]. A meta-analysis by Xu et al. did not find that vitamin D reduced the risk of ovarian cancer. While important, this study focused primarily on vitamin D and calcium intake, rather than serum vitamin D levels [50]. Similarly, a meta-analysis by Yin et al. found a tentative inverse association between circulating vitamin D and ovarian cancer, but this did not reach statistical significance, and the authors emphasized the need for further research [41].
We also found significantly lower vitamin D concentrations in patients with endometrial cancer compared to non-oncological patients. A relationship was also noted between endometrial cancer risk and geographical latitude, solar radiation exposure, and vitamin D levels [53,54,55]. A meta-analysis by McCullough et al. found no significant association between vitamin D intake and endometrial cancer risk; however, it should be noted that this study evaluated intake rather than circulating levels. As noted by Punnonen et al., diet alone may be an insufficient source of vitamin D—a point also acknowledged in this meta-analysis, which emphasized the need for studies including serum vitamin D levels and sun exposure assessments [34,55]. A nested case–control study by Zeleniuch-Jacquotte et al. also showed no link between circulating vitamin D and endometrial cancer risk [56]. Conversely, Yu et al. showed that dietary vitamin D may mitigate the carcinogenic impact of obesity on the endometrium [57]. Given the limited number of studies, more research is needed to draw firm conclusions.
Vitamin D is also believed to have an inhibitory effect on cervical cancer [58,59,60]. A higher incidence of vitamin D deficiency was observed in patients with cervical intraepithelial neoplasia (CIN) and invasive cervical cancer [16,18,61]. It has been shown that vitamin D may have a protective effect on cervical cancer by reducing the expression of oncogenic proteins and inhibiting the proliferation of cell lines [19,62]. While HPV infection is the primary cause of cervical cancer, vitamin D may influence the HPV life cycle through antiviral effects [18]. A randomized trial by Vahedpoor et al. showed the significant regression of CIN1 lesions over a 6-month period in women treated with vitamin D compared to those without supplementation [16].
To our knowledge, no studies compared vitamin D concentrations across different histopathological types of gynecological cancers. In our study, we did not find that any particular histopathological type, including ovarian cancer, was associated with significantly lower vitamin D levels. However, due to the small number of patients with rare histopathological types, further studies on larger cohorts seem justified.
Most studies to date confirm that populations living in urban areas have lower vitamin D concentrations compared to rural populations [63,64,65,66,67,68,69,70]. However, some studies have reported the opposite, with higher levels in city residents [71]. In our study, we did not find lower vitamin D levels among rural patients compared to urban ones. Notably, we observed significantly lower vitamin D concentrations among urban oncology patients, a trend not seen in rural patients. It should be emphasized that the rural patient group in our study was much smaller, and place of residence was not the primary focus of our investigation.
In clinical practice, attention is paid to the treatment of vitamin D deficiency. In our department, as part of the prehabilitation program for patients scheduled for ovarian cancer surgery, one of the recommended interventions is preoperative vitamin D supplementation, especially in deficient patients [72]. Among those in the program, a significant increase in vitamin D levels was observed during the prehabilitation period. While there is no strong evidence that higher vitamin D levels reduce postoperative complications, supplementation is recommended due to its general health benefits, improved prognosis, and reduced chemotherapy-related side effects [73].
A key strength of our study is the large number of patients included, particularly those with ovarian, endometrial, and cervical cancers. To our knowledge, we are the first to analyze vitamin D levels across various histopathological types of ovarian cancer. Additionally, the patient group was homogeneous in terms of ethnicity and skin color, which is important when studying vitamin D concentrations.
Nonetheless, our study has several important limitations. First, it is retrospective in design, which carries inherent limitations. We lacked data on prior vitamin D supplementation in both groups; however, given the large sample size, we believe any impact on the results is minimal. Additionally, we could not assess lifestyle, physical activity, occupational exposure, or socioeconomic status—all factors that may influence vitamin D levels. Another limitation is that vitamin D was assessed only once, on the day of surgical admission, with no prior measurements available. Finally, although the overall patient number was substantial, the sample size for rare histopathological types of ovarian cancer was too small for statistically significant conclusions.

5. Conclusions

In conclusion, our study demonstrated significant vitamin D deficiency among oncology patients compared to non-oncological controls. Specifically, patients with ovarian and endometrial cancer exhibited markedly lower vitamin D levels. While we did not find a relationship between the vitamin D concentration and specific histopathological types of cancer, this is the first analysis of its kind, and further research is needed. Additionally, cancer patients living in urban areas had significantly lower vitamin D levels compared to non-oncological individuals, a pattern not observed among rural residents. In our patient population, ovarian and endometrial cancers were frequently associated with vitamin D deficiency. While this observation does not establish causation, it highlights the potential value of monitoring vitamin D levels and addressing deficiencies as part of broader cancer prevention and management strategies.

Author Contributions

Conceptualization, M.A.Z., P.Z. and K.N.; methodology, M.A.Z., P.Z., A.K. and K.N.; validation, K.N.; formal analysis, A.K.; investigation, M.A.Z. and P.Z.; resources, M.A.Z., P.Z. and K.N.; data curation, P.Z.; writing—original draft preparation, M.A.Z. and P.Z. writing—review and editing, K.N., A.K. and M.A.Z.; visualization, M.A.Z., A.K. and K.N.; supervision, K.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Medical University of Silesia, Katowice, Poland.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Data are contained within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Piatek, K.; Schepelmann, M.; Kallay, E. The Effect of Vitamin D and Its Analogs in Ovarian Cancer. Nutrients 2022, 14, 3867. [Google Scholar] [CrossRef] [PubMed]
  2. Christakos, S.; Dhawan, P.; Verstuyf, A.; Verlinden, L.; Carmeliet, G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol. Rev. 2016, 96, 365–408. [Google Scholar] [CrossRef] [PubMed]
  3. Pittas, A.G.; Chung, M.; Trikalinos, T.; Mitri, J.; Brendel, M.; Patel, K.; Lichtenstein, A.H.; Lau, J.; Balk, E.M. Systematic review: Vitamin D and cardiometabolic outcomes. Ann. Intern. Med. 2010, 152, 307–314. [Google Scholar] [CrossRef]
  4. Garland, C.F.; Garland, F.C.; Gorham, E.D.; Lipkin, M.; Newmark, H.; Mohr, S.B.; Holick, M.F. The role of vitamin D in cancer prevention. Am. J. Public. Health 2006, 96, 252–261. [Google Scholar] [CrossRef]
  5. Deuster, E.; Jeschke, U.; Ye, Y.; Mahner, S.; Czogalla, B. Vitamin D and VDR in Gynecological Cancers-A Systematic Review. Int. J. Mol. Sci. 2017, 18, 2328. [Google Scholar] [CrossRef]
  6. Mueller, P.R.; Kershner, A.J.; Breitrick, B.I.; Keller, K.N.; Radtke, R.L.; Patel, R.J.; Gierach, K.; Arvedson, J.; Moyle-Heyrman, G.E.; Pearson, D.A. Vitamin D and docosahexaenoic acid inhibit proliferation of the ovarian cancer cell line OVCAR4. Nutr. Health 2023. [Google Scholar] [CrossRef] [PubMed]
  7. Ong, J.S.; Cuellar-Partida, G.; Lu, Y.; Fashing, P.A.; Hein, A.; Burghaus, S.; Beckmann, M.W.; Lambrechts, D.; Van Nieuwenhuysen, E.; Vergote, I.; et al. Association of vitamin D levels and risk of ovarian cancer: A Mendelian randomization study. Int. J. Epidemiol. 2016, 45, 1619–1630. [Google Scholar] [CrossRef]
  8. Ong, J.S.; Dixon-Suen, S.C.; Han, X.; An, J.; Liyanage, U.; Dusingize, J.C.; Schumacher, J.; Gockel, I.; Bohmer, A.; Jankowski, J. A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. Nat. Commun. 2021, 12, 246. [Google Scholar] [CrossRef]
  9. Jiang, F.; Li, P.; Fornace, A.J., Jr.; Nicosia, S.V.; Bai, W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J. Biol. Chem. 2003, 278, 48030–48040. [Google Scholar] [CrossRef]
  10. Li, P.; Li, C.; Zhao, X.; Zhang, X.; Nicosia, S.V.; Bai, W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J. Biol. Chem. 2004, 279, 25260–25267. [Google Scholar] [CrossRef]
  11. Yin, L.; Ordóñez-Mena, J.M.; Chen, T.; Schöttker, B.; Arndt, V.; Brenner, H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and meta-analysis. Prev. Med. 2013, 57, 753–764. [Google Scholar] [CrossRef] [PubMed]
  12. Wang, L.; Zhou, S.; Guo, B. Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2. Int. J. Mol. Sci. 2020, 21, 2334. [Google Scholar] [CrossRef] [PubMed]
  13. Liu, Y.; Li, C.; Chen, P.; Li, X.; Li, M.; Guo, H.; Li, J.; Chu, R.; Wang, H. Polymorphisms in the vitamin D Receptor (VDR) and the risk of ovarian cancer: A meta-analysis. PLoS ONE 2013, 8, e66716. [Google Scholar] [CrossRef] [PubMed]
  14. Jung, S.; Jin, S.; Je, Y. Vitamin D Intake, Blood 25-Hydroxyvitamin D, and Risk of Ovarian Cancer: A Meta-Analysis of Observational Studies. J. Women’s Heal. 2023, 32, 561–573. [Google Scholar] [CrossRef]
  15. Hosono, S.; Matsuo, K.; Kajiyama, H.; Hirose, K.; Suzuki, T.; Kawase, T.; Kidokoro, K.; Nakanishi, T.; Hamajima, N.; Kikkawa, F. Association between dietary calcium and vitamin D intake and cervical carcinogenesis among Japanese women. Eur. J. Clin. Nutr. 2010, 64, 400–409. [Google Scholar] [CrossRef]
  16. Vahedpoor, Z.; Jamilian, M.; Bahmani, F.; Aghadavod, E.; Karamali, M.; Kashanian, M.; Asemi, Z. Effects of Long-Term Vitamin D Supplementation on Regression and Metabolic Status of Cervical Intraepithelial Neoplasia: A Randomized, Double-Blind, Placebo-Controlled Trial. Horm. Cancer 2017, 8, 58–67. [Google Scholar] [CrossRef]
  17. Özgü, E.; Yılmaz, N.; Başer, E.; Güngör, T.; Erkaya, S.; Yakut, H.İ. Could 25-OH vitamin D deficiency be a reason for HPV infection persistence in cervical premalignant lesions? J. Exp. Ther. Oncol. 2016, 11, 177–180. [Google Scholar]
  18. Wang, G.; Lei, L.; Zhao, X.; Zhang, J.; Zhou, M.; Nan, K. Calcitriol Inhibits Cervical Cancer Cell Proliferation Through Downregulation of HCCR1 Expression. Oncol. Res. 2014, 22, 301–309. [Google Scholar] [CrossRef]
  19. González-Duarte, R.J.; Cázares-Ordoñez, V.; Romero-Córdoba, S.; Diaz, L.; Ortiz, V.; Freyre-Gonzalez, J.A.; Hidalgo-Miranda, A.; Larrea, F.; Avila, E. Calcitriol increases Dicer expression and modifies the microRNAs signature in SiHa cervical cancer cells. Biochem. Cell Biol. 2015, 93, 376–384. [Google Scholar] [CrossRef]
  20. Guo, H.; Guo, J.; Xie, W.; Yuan, L.; Sheng, X. The role of vitamin D in ovarian cancer: Epidemiology, molecular mechanism and prevention. J. Ovarian Res. 2018, 11, 71. [Google Scholar] [CrossRef]
  21. Shen, Z.; Zhang, X.; Tang, J.; Kasiappan, R.; Jinwal, U.; Li, P.; Hann, S.; Nicosia, S.V.; Wu, J.; Zhang, X.; et al. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells. Mol. Cell Endocrinol. 2011, 338, 58–67. [Google Scholar] [CrossRef] [PubMed]
  22. Hou, Y.F.; Gao, S.H.; Wang, P.; Zhang, H.M.; Liu, L.Z.; Ye, M.X.; Zhou, G.M.; Zhang, Z.L.; Li, B.Y. 1α,25(OH)2D3 Suppresses the Migration of Ovarian Cancer SKOV-3 Cells through the Inhibition of Epithelial-Mesenchymal Transition. Int. J. Mol. Sci. 2016, 17, 1285. [Google Scholar] [CrossRef] [PubMed]
  23. Jiang, F.; Bao, J.; Li, P.; Nicosia, S.V.; Bai, W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J. Biol. Chem. 2004, 279, 53213–53221. [Google Scholar] [CrossRef]
  24. Thill, M.; Woeste, A.; Reichert, K.; Fisher, D.; Rody, A.; Friedrich, M.; Koster, F. Vitamin D inhibits ovarian cancer cell line proliferation in combination with celecoxib and suppresses cyclooxygenase-2 expression. Anticancer. Res. 2015, 35, 1197–1203. [Google Scholar]
  25. Dovnik, A.; Dovnik, N.F. Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms. Cells 2020, 9, 335. [Google Scholar] [CrossRef]
  26. Lungchukiet, P.; Sun, Y.; Kasiappan, R.; Quarni, W.; Nicosia, S.V.; Zhang, X.; Bai, W. Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor. J. Steroid. Biochem. Mol. Biol. 2015, 148, 138–147. [Google Scholar] [CrossRef]
  27. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930. [Google Scholar] [CrossRef]
  28. Institute of Medicine (US). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross, A.C., Taylor, C.L., Yaktine, A.L., Del Valle, H.B., Eds.; Dietary Reference Intakes for Calcium and Vitamin D; National Academies Press: Washington, DC, USA, 2011. [Google Scholar]
  29. Cashman, K.D.; Dowling, K.G.; Škrabáková, Z.; Gonzalez-Gross, M.; Valtuena, J.; De Henauw, S.; Moreno, L.; Damsgaard, C.T.; Michaelsen, K.F.; Molgaard, C.; et al. Vitamin D deficiency in Europe: Pandemic? Am. J. Clin. Nutr. 2016, 103, 1033–1044. [Google Scholar] [CrossRef]
  30. Cashman, K.D. Global differences in vitamin D status and dietary intake: A review of the data. Endocr. Connect. 2022, 11, e210282. [Google Scholar] [CrossRef]
  31. McKenna, M.J. Differences in vitamin D status between countries in young adults and the elderly. Am. J. Med. 1992, 93, 69–77. [Google Scholar] [CrossRef]
  32. Barrea, L.; Frias-Toral, E.; Pugliese, G.; Garcia-Velasquez, E.; DE Los Angeles Carignano, M.; Savastano, S.; Colao, A.; Muscogiuri, G. Vitamin D in obesity and obesity-related diseases: An overview. Minerva Endocrinol. 2021, 46, 177–192. [Google Scholar] [CrossRef] [PubMed]
  33. Avila, E.; Noriega-Mejía, B.J.; González-Macías, J.; Cortes-Hernandez, U.; Garcia-Quiroz, J.; Garcia-Becerra, R.; Diaz, L. The Preventive Role of the Vitamin D Endocrine System in Cervical Cancer. Int. J. Mol. Sci. 2023, 24, 8665. [Google Scholar] [CrossRef] [PubMed]
  34. Punnonen, R.; Gillespy, M.; Hahl, M.; Koskinen, T.; Notelovitz, M. Serum 25-OHD, vitamin A and vitamin E concentrations in healthy Finnish and Floridian women. Int. J. Vitam. Nutr. Res. 1988, 58, 37–39. [Google Scholar] [PubMed]
  35. Holick, M.F. Resurrection of vitamin D deficiency and rickets. J. Clin. Investig. 2006, 116, 2062–2072. [Google Scholar] [CrossRef]
  36. Webb, A.R.; Kline, L.; Holick, M.F. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J. Clin. Endocrinol. Metab. 1988, 67, 373–378. [Google Scholar] [CrossRef]
  37. Garland, C.F.; Mohr, S.B.; Gorham, E.D.; Grant, W.B.; Garland, F.C. Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am. J. Prev. Med. 2006, 31, 512–514. [Google Scholar] [CrossRef]
  38. Yin, L.; Grandi, N.; Raum, E.; Haug, U.; Arndt, V.; Brenner, H. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecol. Oncol. 2011, 121, 369–375. [Google Scholar] [CrossRef]
  39. Grant, W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94, 1867–1875. [Google Scholar] [CrossRef]
  40. Grant, W.B. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res. 2003, 164, 371–377. [Google Scholar] [CrossRef]
  41. Lefkowitz, E.S.; Garland, C.F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int. J. Epidemiol. 1994, 23, 1133–1136. [Google Scholar] [CrossRef]
  42. Freedman, D.M.; Dosemeci, M.; McGlynn, K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: A composite death certificate based case-control study. Occup. Env. Med. 2002, 59, 257–262. [Google Scholar] [CrossRef] [PubMed]
  43. Salazar-Martinez, E.; Lazcano-Ponce, E.C.; Gonzalez Lira-Lira, G.; Escudero-De los Rios, P.; Hernandez-Avila, M. Nutritional determinants of epithelial ovarian cancer risk: A case-control study in Mexico. Oncology 2002, 63, 151–157. [Google Scholar] [CrossRef] [PubMed]
  44. Bakhru, A.; Mallinger, J.B.; Buckanovich, R.J.; Griggs, J.J. Casting light on 25-hydroxyvitamin D deficiency in ovarian cancer: A study from the NHANES. Gynecol. Oncol. 2010, 119, 314–318. [Google Scholar] [CrossRef] [PubMed]
  45. Walentowicz-Sadlecka, M.; Grabiec, M.; Sadlecki, P.; Gotowska, M.; Walentowicz, P.; Krintus, M.; Mankowska-Cyl, A.; Sypniewska, G. 25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clin. Biochem. 2012, 45, 1568–1572. [Google Scholar] [CrossRef]
  46. Webb, P.M.; de Fazio, A.; Protani, M.M.; Ibiebele, T.I.; Nagle, C.M.; Brand, A.H.; Blomfield, P.I.; Grant, P.; Perrin, L.C.; Neale, R.E.; et al. Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. Am. J. Clin. Nutr. 2015, 102, 109–114. [Google Scholar] [CrossRef]
  47. Keum, N.; Lee, D.H.; Greenwood, D.C.; Manson, J.E.; Giovannucci, E. Vitamin D supplementation and total cancer incidence and mortality: A meta-analysis of randomized controlled trials. Ann. Oncol. 2019, 30, 733–743. [Google Scholar] [CrossRef]
  48. Dimitrakopoulou, V.I.; Tsilidis, K.K.; Haycock, P.C.; Dimou, N.L.; Al-Dabhani, K.; Martin, R.M.; Lewis, S.J.; Gunter, M.J.; Mondul, A.; Shui, I.M.; et al. Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. BMJ 2017, 359, j4761. [Google Scholar] [CrossRef]
  49. Sajo, E.A.; Okunade, K.S.; Olorunfemi, G.; Rabiu, K.A.; Anorlu, R.I. Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria. E Cancer Med. Sci. 2020, 14, 1078. [Google Scholar] [CrossRef]
  50. Xu, J.; Chen, K.; Zhao, F.; Huang, D.; Zhang, H.; Fu, Z.; Xu, J.; Wu, Y.; Lin, H.; Zhou, Y.; et al. Association between vitamin D/calcium intake and 25-hydroxyvitamin D and risk of ovarian cancer: A dose-response relationship meta-analysis. Eur. J. Clin. Nutr. 2021, 75, 417–429. [Google Scholar] [CrossRef]
  51. Zheng, W.; Danforth, K.N.; Tworoger, S.S.; Goodman, M.T.; Arslan, A.A.; Patel, A.V.; McCullough, M.L.; Weinstein, S.J.; Kolonel, L.N.; Purdue, M.P.; et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol. 2010, 172, 70–80. [Google Scholar] [CrossRef]
  52. Mohr, S.B.; Garland, C.F.; Gorham, E.D.; Grant, W.B.; Garland, F.C. Is ultraviolet B irradiance inversely associated with incidence rates of endometrial cancer: An ecological study of 107 countries. Prev. Med. 2007, 45, 327–331. [Google Scholar] [CrossRef] [PubMed]
  53. Grant, W.B. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int. J. Cancer 2007, 120, 1123–1128. [Google Scholar] [CrossRef] [PubMed]
  54. Epstein, E.; Lindqvist, P.G.; Geppert, B.; Olsson, H. A population-based cohort study on sun habits and endometrial cancer. Br. J. Cancer 2009, 101, 537–540. [Google Scholar] [CrossRef] [PubMed]
  55. McCullough, M.L.; Bandera, E.V.; Moore, D.F.; Kushi, L.H. Vitamin D and calcium intake in relation to risk of endometrial cancer: A systematic review of the literature. Prev. Med. 2008, 46, 298–302. [Google Scholar] [CrossRef]
  56. Zeleniuch-Jacquotte, A.; Gallicchio, L.; Hartmuller, V.; Helzlsouer, K.J.; McCullough, M.L.; Setiawan, V.W.; Shu, X.O.; Weinstein, S.J.; Weiss, J.M.; Arslan, A.A. Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol. 2010, 172, 36–46. [Google Scholar] [CrossRef]
  57. Yu, W.; Cline, M.; Maxwell, L.G.; Berrigan, D.; Rodriguez, G.; Warri, A.; Hilakivi-Clarke, L. Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/− mice. Cancer Prev. Res. 2010, 3, 1246–1258. [Google Scholar] [CrossRef]
  58. Dong, H.; Chen, S.; Liang, X.; Cai, Q.; Zhang, X.; Xie, J.; Sun, Z. Vitamin D and Its Receptors in Cervical Cancer. J. Cancer 2024, 15, 926–938. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  59. Vuolo, L.; Di Somma, C.; Faggiano, A.; Colao, A. Vitamin D and cancer. Front. Endocrinol. 2012, 3, 58. [Google Scholar] [CrossRef]
  60. Ono, A.; Koshiyama, M.; Nakagawa, M.; Watanabe, Y.; Ikuta, E.; Seki, K.; Oowaki, M. The Preventive Effect of Dietary Antioxidants on Cervical Cancer Development. Medicina 2020, 56, 604. [Google Scholar] [CrossRef]
  61. Vahedpoor, Z.; Mahmoodi, S.; Samimi, M.; Gilasi, H.R.; Bahmani, F.; Soltani, A.; Esfahani, M.S.; Asemi, Z. Long-Term Vitamin D Supplementation and the Effects on Recurrence and Metabolic Status of Cervical Intraepithelial Neoplasia Grade 2 or 3: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann. Nutr. Metab. 2018, 72, 151–160. [Google Scholar] [CrossRef]
  62. Avila, E.; García-Becerra, R.; Rodríguez-Rasgado, J.A.; Diaz, L.; Ordaz-Rosado, D.; Zugel, U.; Steinmeyer, A.; Barrera, D.; Halhali, A.; Larrea, F.; et al. Calcitriol down-regulates human ether a go-go 1 potassium channel expression in cervical cancer cells. Anticancer Res. 2010, 30, 2667–2672. [Google Scholar] [PubMed]
  63. Christopher, K.L.; Wiggins, A.T.; Van Meter, E.M.; Means, R.T., Jr.; Hayslip, J.W.; Roach, J.P. Differences in vitamin D nutritional status between newly diagnosed cancer patients from rural or urban settings in Kentucky. Nutr. Cancer 2013, 65, 653–658. [Google Scholar] [CrossRef] [PubMed]
  64. Islam, M.Z.; Lamberg-Allardt, C.; Kärkkäinen, M.; Outila, T.; Salamatullah, Q.; Shamim, A.A. Vitamin D deficiency: A concern in premenopausal Bangladeshi women of two socio-economic groups in rural and urban region. Eur. J. Clin. Nutr. 2002, 56, 51–56. [Google Scholar] [CrossRef]
  65. Nurbazlin, M.; Chee, W.S.; Rokiah, P.; Tan, A.T.; Chew, Y.Y.; Nusaibach, A.R.; Chan, S.P. Effects of sun exposure on 25(OH) vitamin D concentration in urban and rural women in Malaysia. Asia Pac. J. Clin. Nutr. 2013, 22, 391–399. [Google Scholar] [CrossRef]
  66. Maddah, M.; Sharami, S.H.; Neyestani, T.R. Vitamin D insufficiency among postmenopausal women in urban and rural areas in Guilan, Northern Iran. J. Nutr. Elder. 2009, 28, 386–393. [Google Scholar] [CrossRef]
  67. Bojar, I.; Raczkiewicz, D.; Sarecka-Hujar, B. Depression, Metabolic Syndrome, Serum TSH, and Vitamin D Concentrations in Rural and Urban Postmenopausal Women. Medicina 2020, 56, 511. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  68. Anwar, S.; Iqbal, M.P.; Azam, I.; Habib, A.; Bhutta, S.; Soofi, S.B.; Bhutta, Z.A. Urban and rural comparison of vitamin D status in Pakistani pregnant women and neonates. J. Obs. Gynaecol. 2016, 36, 318–323. [Google Scholar] [CrossRef]
  69. Praveen, P.A.; Singh, A.; Lakshmy, R.; Amarchand, R.; Berry, P.; Krishnan, A.; Prabhakaran, D.; Tandon, N.; Roy, A. Prevalence and Correlates of Vitamin D Deficiency among Adult Population in Urban and Rural Areas of the National Capital Region of Delhi, India. WHO South-East Asia J. Public Heal. 2023, 12, 104–109. [Google Scholar] [CrossRef]
  70. Chávez-Courtois, M.; Godínez-Martínez, E.; Muñoz-Manrique, C.; Negrete-Martínez, V.; González-Leyva, C.P.; Tolentino-Dolores, M.; Suárez-Rico, B.; Estrada-Gutierrez, G.; Perichart-Perera, O. Vitamin D Status and Its Determinants in Mexican Pregnant Women from a Rural and an Urban Area: A Comparative Study. Int. J. Environ. Res. Public Health 2021, 18, 4571. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  71. Fang, F.; Wei, H.; Wang, K.; Tan, L.; Zhang, W.; Ding, L.; Liu, T.; Shan, Z.; Zhu, M. High prevalence of vitamin D deficiency and influencing factors among urban and rural residents in Tianjin, China. Arch. Osteoporos. 2018, 13, 64. [Google Scholar] [CrossRef] [PubMed]
  72. Zębalski, M.A.; Parysek, K.; Krzywon, A.; Nowosielski, K. LUNA EMG as a Marker of Adherence to Prehabilitation Programs and Its Effect on Postoperative Outcomes among Patients Undergoing Cytoreductive Surgery for Ovarian Cancer and Suspected Ovarian Tumors. Cancers 2024, 16, 2493. [Google Scholar] [CrossRef] [PubMed]
  73. Zeng, X.; Zhang, L.; Jia, S.; Lin, T.; Liu, G.; Yue, J.; Huang, X. Effects of Circulating 25(OH)D Status in Advanced Colorectal Cancer Patients Undergoing Chemotherapy: A Systematic Review. Anticancer. Res. 2021, 41, 5903–5912. [Google Scholar] [CrossRef] [PubMed]
Cancers 17 01987 g001
Figure 1. Comparison of vitamin D levels in oncological and non-oncological patients.
Figure 1. Comparison of vitamin D levels in oncological and non-oncological patients.
Cancers 17 01987 g001
Cancers 17 01987 g002
Figure 2. Vitamin D concentration in individual histopathological types of ovarian cancer.
Figure 2. Vitamin D concentration in individual histopathological types of ovarian cancer.
Cancers 17 01987 g002
Table 1. Baseline characteristics of oncological and non-oncological patients.
Table 1. Baseline characteristics of oncological and non-oncological patients.
CharacteristicOncological Patients
(n Total = 472)		Non-Oncological Patients
(n Total = 214)		p-Value
Age [years], (SD)56 (14)56 (14)p > 0.05
BMI [kg/m2], (SD)27 (6)27 (6)p > 0.05
City inhabitant, n/n total (%)407/472 (86)189/214 (88)p > 0.05
Diabetes, n/n total (%)86/472 (18)26/214 (12)p > 0.05
Hypertension, n/n total (%)197/472 (42)81/214 (38)p > 0.05
Ischemic heart disease, n/n total (%)33/472 (7)13/214 (6)p > 0.05
Smoking, n/n total (%)103/472 (22)47/214 (22)p > 0.05
Use of oral contraceptives, n/n total (%)23/472 (4.8)13/214 (6.1)p > 0.05
Abbreviations: SD—standard deviation, BMI—body mass index.
Table 2. Detailed characteristics and histopathological results of patients in both groups.
Table 2. Detailed characteristics and histopathological results of patients in both groups.
CharacteristicNumber of Patients
Oncological patients, n/n total (%)472/686 (68.8)
Ovarian cancer, n/n total of oncological patients (%)283/472 (60)
Endometrial cancer, n/n total of oncological patients (%)135/472 (29)
Cervical cancer, n/n total of oncological patients (%)54/472 (11)
Non-oncological patients, n/n total (%)214/686 (31.2)
Uterine fibroid, n/n total of non-oncologic patients (%)52/214 (24.3)
Benign ovarian lesions, n/n total of non-oncologic patients (%)162/214 (75.7)
Serous adenoma, n/n total of benign ovarian lesions (%)22/162 (13.6)
Mucous adenoma, n/n total of benign ovarian lesions (%)12/162 (7.4)
Teratoma, n/n total of benign ovarian lesions (%)11/162 (6.8)
Fibroma, n/n total of benign ovarian lesions (%)3/162 (1.9)
Thecoma, n/n total of benign ovarian lesions (%)2/162 (1.2)
Benign Brenner tumor, n/n total of benign ovarian lesions (%)3/162 (1.9)
Sertoli-Leydig cell tumor, n/n total of benign ovarian lesions (%)2/162 (1.2)
Endometrial cyst, n/n total of benign ovarian lesions (%)16/162 (9.9)
Hemorrhagic cyst, n/n total of benign ovarian lesions (%)14/162 (8.6)
Serous cyst, n/n total of benign ovarian lesions (%)77/162 (47.5)
Table 3. Comparison of vitamin D concentrations in ovarian, endometrial and cervical cancers compared to non-oncological patients.
Table 3. Comparison of vitamin D concentrations in ovarian, endometrial and cervical cancers compared to non-oncological patients.
Type of Cancer vs. Non-Oncological PatientsNumber of PatientsVitamin D Concentration (Median [IQR], ng/mLp-Value
Ovarian cancer
vs.
non-oncological patients		28322 (16, 32) 
vs.vs.<0.01
21428 (21, 36) 
Endometrial cancer
vs.
non-oncological patients		13524 (18, 35) 
vs.
214		vs.
28 (21, 36)		<0.01
Cervical cancer
vs.
non-oncological patients		5426 (20, 31) 
vs.
214		vs.
28 (21, 36)		0.1
Abbreviations: IQR—interquartile range.
Table 4. Median vitamin D concentrations by residence and disease status.
Table 4. Median vitamin D concentrations by residence and disease status.
CharacteristicNumber of PatientsNon-Oncological Patients from Countryside, n = 25Oncological Patients from Countryside, n = 65Non-Oncological Patients from City, n = 189Oncological Patients from City, n = 408p-Value
Vitamin D concentration, median [IQR] (ng/mL)68629 (22, 36)24 (19, 32)27 (21, 36)23 (17, 33)<0.001
Abbreviations: IQR—interquartile range.
Table 5. Change in vitamin D concentration during prehabilitation.
Table 5. Change in vitamin D concentration during prehabilitation.
CharacteristicBeginning of Prehabilitation ProgramEnd of Prehabilitation ProgramChange *p-Value
Vitamin D concentration, median [IQR] (ng/mL)23 (17, 33)35 (28, 46)8 (1, 18)<0.001
Abbreviations: IQR—interquartile range. * The difference in vitamin D concentration during prehabilitation program.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zębalski, M.A.; Zębalska, P.; Krzywon, A.; Nowosielski, K. Vitamin D Concentration Among Women with Gynecological Cancers. Cancers 2025, 17, 1987. https://doi.org/10.3390/cancers17121987

AMA Style

Zębalski MA, Zębalska P, Krzywon A, Nowosielski K. Vitamin D Concentration Among Women with Gynecological Cancers. Cancers. 2025; 17(12):1987. https://doi.org/10.3390/cancers17121987

Chicago/Turabian Style

Zębalski, Marcin Adam, Patrycja Zębalska, Aleksandra Krzywon, and Krzysztof Nowosielski. 2025. "Vitamin D Concentration Among Women with Gynecological Cancers" Cancers 17, no. 12: 1987. https://doi.org/10.3390/cancers17121987

APA Style

Zębalski, M. A., Zębalska, P., Krzywon, A., & Nowosielski, K. (2025). Vitamin D Concentration Among Women with Gynecological Cancers. Cancers, 17(12), 1987. https://doi.org/10.3390/cancers17121987

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop